The purpose of this study is to evaluate the pharmacokinetics of a single 2 mg oral dose of
prucalopride in subjects with various degrees of renal impairment compared with normal renal
function and to monitor the safety profile of prucalopride in subjects with renal impairment.
Hypothesis:
Prucalopride might accumulate and exhibit a different pharmacokinetic profile in renally
impaired subjects compared with the normal population.